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Conclusions: New-onset AF during hospitalization for
STEMI is an independent risk factor for adverse outcomes
at 90 days in patients treated with primary PCI.
Perspective: The study demonstrates that AF is associated
with worse outcomes after PCI in patients with STEMI.
Warfarin was underutilized in these patients, explaining the
higher risk of stroke. However, whether AF was directly
responsible for the higher risk of death, heart failure, and
shock is unclear. Despite multivariate analysis, it still is pos-
sible that AF was a marker of unmeasured variables that
resulted in adverse outcomes.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Characterization and Outcome of Patients With
Severe Symptomatic Aortic Stenosis Referred for
Percutaneous Aortic Valve Replacement
Kapadia SR, Goel SS, Svensson L, et al.
J Thorac Cardiovasc Surg 2009;137:1430-1435.
Study Design: What are the characteristics and outcomes of
patients currently referred for percutaneous aortic valve
replacement (AVR)?
Methods: Between February 2006 and March 2007, 92 patients
were screened for percutaneous AVR. Clinical and echocar-
diographic characteristics were compared for patients
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Arrhythmias
Antithrombotic Therapy and Outcomes of Patients
With Atrial Fibrillation Following Primary
Percutaneous Coronary Intervention: Results From
the APEX-AMI Trial
Lopes RD, Elliott LE, White HD, et al.
Eur Heart J 2009;Jun 6:[Epub ahead of print].
Study Design: How does atrial fibrillation (AF) affect outcomes
in patients with ST-segment elevation myocardial infarction
(STEMI) treated by primary percutaneous coronary interven-
tion (PCI)?
Methods: This was a post-hoc analysis of 5,745 patients
(mean age 63 years) with STEMI treated by PCI in a trial
of pexelizumab versus placebo. AF was detected with elec-
trocardiograms recorded upon admission, during
hospitalization, and at discharge.
Results: Overall, 11% of patients had AF during the hospital-
ization: 4.8% upon admission, 6.3% with new-onset AF
during the hospitalization, and 2.5% at discharge. Among
patients without AF, 96%, 89%, and 5% received aspirin,
clopidogrel, and warfarin, respectively, whereas among
patients with AF at discharge, 86%, 81%, and 43% received
aspirin, clopidogrel, and warfarin, respectively. New-onset
AF was associated with an 80% higher risk of 90-day mor-
tality, and was associated with >2-fold increase in risk of
heart failure, stroke, and shock at 90 days.
Results: The study cohort was comprised of 625 CAS cases. A
majority of cases were performed by cardiologists (Card)
(378; 60.5%), whereas vascular surgeons (VS) (199; 31.8%)
and interventional radiologists (RAD) (48; 7.7%) performed
the rest. The stroke rate was 2.72% and did not differ by spe-
cialty. The overall cardiac complication rate (2.4%) was also
not influenced by physician specialty. Average hospital length
of stay was significantly shorter for VS (1.64 days) compared
with RAD (2.83 days, p = 0.0167) and Card (2.14 days, p =
0.0649). Mean total hospital cost was significantly greater for
RAD ($20,987) and Card ($18,182) than for VS ($10,000).
Medical supply costs were significantly greater for Card
($8,772) than for VAS ($3,354) and RAD ($4,964). Total
hospital cost, length of stay, and medical supplies were signif-
icantly lower for high-volume practitioners (>20 procedures).
Conclusions: In this cohort, the specialty of the operator did
not impact the outcome of CAS, but was significantly asso-
ciated with variation in resource utilization.
Perspective: This study corroborates earlier data suggesting that
physician specialty does not significantly impact procedural
outcome of patients undergoing CAS. It is not clear if varia-
tion in resource use is due to differences in patient
characteristics or is influenced by dissimilarity in the interven-
tional approach. This needs further investigation to assess if
the cost saving can be reproduced across all specialties. 
Summary written by: Hitinder S. Gurm, MD 
Congenital Heart Disease
Kawasaki Disease in Children
Wood LE, Tulloh RM.
Heart 2009;95:787-792. 
Perspective: The following are 10 points to remember regard-
ing this review on Kawasaki disease (KD): 
1. KD generally occurs in children ages 6 months to 5 years,
with a peak incidence in infants ages 9-11 months. 
2. The precise etiology of KD remains unknown. The gen-
eral feeling is that a common infectious agent evokes an
abnormal immunological response in subjects with a genetic
predisposition. 
3. The American Heart Association diagnosis of KD
includes presence of at least four of these five criteria: bilat-
eral nonpurulent conjunctivitis, erythematous oral cavity,
polymorphous maculopapular skin rash, cervical lym-
phadenopathy, and erythema/edema of the hands and feet
with desquamation occurring later in the illness. Fever must
be of greater than 5-day duration. 
undergoing surgical AVR, percutaneous AVR, balloon aortic
valvotomy, or no intervention. A primary endpoint of all-
cause mortality was compared between groups.
Results: Of 92 patients screened, 19 patients underwent sur-
gical AVR, 18 patients underwent percutaneous AVR, and
36 patients had no intervention. Balloon aortic valvotomy
was performed in 30 patients, of whom 8 were bridged to
percutaneous AVR and 3 to surgical AVR. Of the remain-
ing 19 patients, bridging to percutaneous AVR could not be
accomplished because of death (n = 9 [47%]), exclusion
from the percutaneous AVR protocol (n = 6 [32%]), and
improvement after balloon aortic valvotomy with patients
declining subsequent percutaneous AVR (n = 4 [21%]).
Patients not undergoing AVR had higher mortality com-
pared with those undergoing AVR (44% vs. 14%) over a
mean duration of 220 days.
Conclusions: Symptomatic patients with severe aortic stenosis
have high mortality if timely AVR is not feasible. Of
patients referred for percutaneous AVR, 20% underwent
surgical AVR with a good outcome. Unfavorable outcomes
were seen among patients undergoing balloon aortic val-
votomy alone or no intervention.
Perspective: ‘Observation’ or ‘medical management’ for severe
symptomatic aortic stenosis leads to death; and although
percutaneous balloon aortic valvotomy can be a useful bridge
to definitive therapy, it is not a substitute for surgical or per-
cutaneous AVR. Take-home messages are: 1) without
intervention in the form of surgical or percutaneous AVR,
outcomes are abysmal for patients with severe symptomatic
aortic stenosis; and 2) valve surgery should be concentrated
in centers of excellence, where both triage decisions and
interventions can be optimized based on operator experience
and site volume. 
Summary written by: David S. Bach, MD
Carotid Artery Stenting: Impact of Practitioner
Specialty and Volume on Outcomes and Resource
Utilization
Vogel TR, Dombrovskiy VY, Haser PB, Graham AM.
J Vasc Surg 2009;49:1166-1171.
Study Design: Does the specialty of the operator (cardiologist
vs. vascular surgeon vs. radiologist) influence outcome of
carotid artery stenting (CAS)?
Methods: The authors analyzed the 2005-2006 State Inpatient
Databases for New Jersey to assess outcome of patients under-
going CAS. CAS outcomes were analyzed with respect to
practitioner specialty and volume.
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3. Traditional measures of model fitness consist of predictors,
which are statistically significant in terms of their relationship
to the outcome (such as cardiovascular disease [CVD] mortal-
ity). The overall fit of the models adding or subtracting
predictors is assessed using the c-statistic or the area under the
ROC curve. 
4. New methods for risk prediction models include assessment
to determine risk reclassification for single factors by evaluation
of models with and without a single risk factor. The degree to
which patients are reclassified in terms of their risk category is
then examined. 
5. Beyond a percent of individuals reclassified, assessment of
model fit may include a comparison of observed and expected
rates of disease within specific categories of risk. 
6. Net reclassification improvement assesses risk prediction
models by examining the difference in proportions moving up
and down risk strata, comparing cases versus controls; thus
allowing movement in the correct direction to be determined. 
7. Integrated discrimination improvement is the difference in
the slopes between two models with the slope being the mean
difference in the predicted probabilities between cases and con-
trols. 
8. Net reclassification improvement and integrated discrimina-
tion improvement depend on case and control status—neither
measure assesses model calibration and neither is used for cen-
sored data.
9. Use of a test data set, bootstrapping, or cross-validation can
assist in modifying models to improve accuracy.
10. Risk prediction models, to be useful, should have clinical
utility. Additional information, including cost-effectiveness of
recommendations using risk prediction models, will add utility
to these types of models.
Summary written by: Elizabeth A. Jackson, MD 
Exercise Training for Type 2 Diabetes Mellitus:
Impact on Cardiovascular Risk. A Scientific
Statement From the American Heart Association
Marwick TH, Hordern MD, Miller T, et al.
Circulation 2009;119:3244-3262.
Perspective: The following are 10 points to remember about this
scientific statement: 
1. The increasing prevalence of overweight and obesity has led
to an unprecedented epidemic of type 2 diabetes mellitus
(T2DM), and is likely to be followed by an epidemic of compli-
cations. The economic cost has been estimated at $172 billion
in 2007 in the United States. 
4. Common laboratory findings include elevated inflammatory
markers, leukocytosis, white blood cells on urinalysis, throm-
bocytosis later in the disease, and elevated liver function
studies. 
5. Standard therapy for acute KD is infusion of intravenous
immunoglobulin (IVIg) and high-dose aspirin. The majority
of children respond promptly and dramatically to treatment. 
6. Steroids are occasionally used for failure of treatment with
IVIg. 
7. Cardiac manifestations can vary significantly. Sequelae
include coronary artery ectasia, coronary artery aneurysms, and
myocarditis or pericarditis. 
8. Serial echocardiography at the time of acute illness,  at 6
weeks, and at 6 months should be performed. The exam
should include careful assessment of the coronary arteries for
size and aneurysms, mural or intraluminal thrombi, effu-
sions, valve function, and myocardial function.
9. Functional studies of coronary flow, such as stress echocar-
diography, should be considered in patients with KD and
coronary artery involvement.
10. Multiple modalities have been used for intervention for
myocardial ischemia as a result of coronary complications of
KD: coronary artery bypass grafting, balloon angioplasty stent-
ing, rotational ablation, and transluminal coronary
revascularization.
Summary written by: Timothy B. Cotts, MD
General Cardiology
Advances in Measuring the Effect of Individual
Predictors of Cardiovascular Risk: The Role of
Reclassification Measures 
Cook NR, Ridker PM.
Ann Intern Med 2009;150:795-802. 
Perspective: The following are 10 points to remember about
this article: 
1. Risk prediction models are often evaluated using receiver-
operating characteristic (ROC) curves; however, this method
may not be accurate when comparing different risk prediction
models. 
2. Newer methods for comparison of risk prediction models
have been proposed, which may assist in the valuation of
such models. These methods include the stratification of risk
into clinical categories and the assessment of models with
regard to the reclassification of patients into risk categories. 
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2. The beneficial effects of exercise in T2DM are well docu-
mented with regard to glucose control, body mass index,
lipids, hypertension, and changes in vascular endothelial
function, carotid artery intima-media thickness, and arterial
distensibility. 
3. To date, no study has evaluated duration, frequency, and
intensity of exercise necessary. The impact of aerobic and
resistance training on cardiovascular events, morbidity, and
mortality is not clear. 
4. Consensus is that there is no indication for routine screen-
ing of asymptomatic T2DM for coronary disease with stress
ECG, stress imaging, or coronary calcium scores. A stress
test may be recommended before a patient with known coro-
nary artery disease begins an exercise program or if there is a
change in clinical status or no recent (≥2 years) stress test. 
5. Hypoglycemia is the most important potential complica-
tion of exercise in T2DM. Self-monitoring of blood glucose
is the most effective means of avoiding hypoglycemic
episodes during exercise. Adequate replacement of carbohy-
drate may be the most effective strategy for most forms of
exercise. 
6. With prolonged exercise (>60 minutes), insulin dosage
should be reduced by 20-30%. In adolescents on insulin, a
brief maximal sprint after moderate-intensity exercise can
oppose a further fall in blood glucose levels. 
7. In a study designed to treat T2DM with a lifestyle pro-
gram, patients with 3 or more fasting blood glucose (FBG)
<80 mg/dl or >2/week of hypoglycemic spells have their hypo-
glycemic medication dose cut by 50-100%. Those with
modest control have their doses reduced by 25-50%, and
when the FBG is >100 mg/dl, no changes are made. 
8. Peripheral vascular disease involving the conduit and
small vessels is common in T2DM. While exercise should
improve vascular function, care is necessary to prevent and
detect foot complications of exercise. It is important to
avoid high-impact activity and carefully select footwear.
Patients require a regular inspection of the feet by care-
givers, themselves, and partners.
9. Patients with T2DM who were previously sedentary
should aim to accumulate a minimum energy expenditure of
1000 kcal/week, which equates to a minimum 30 minutes of
accumulated moderate-intensity physical activity on 5 days
of the week. To reduce cardiovascular risk, it is recom-
mended that patients with T2DM accumulate a minimum
of 150 minutes/week of at least moderate-intensity physical
activity and/or 90 minutes/week of at least vigorous-inten-
sity cardiorespiratory exercise. Additionally, resistance
training 3 times per week should be encouraged, with no
more than 2 consecutive days without training.
10. Assisting patients with implementing life style changes in
T2DM is the responsibility of physicians, which can be sup-
plemented by diabetic educators, nurses, referral to behavioral
specialists and exercise physiologists, and by use of telephone
exercise counseling. Patients should be encouraged to partici-
pate in community health centers. Financial, time, and other
barriers may limit uptake in some minority groups.
Summary written by: Melvyn Rubenfire, MD 
Standardized Low-Molecular-Weight Heparin
Bridging Regimen in Outpatients on Oral
Anticoagulants Undergoing Invasive Procedure or
Surgery: An Inception Cohort Management Study
Pengo V, Cucchini U, Denas G, et al., on behalf of the Italian Federation
of Centers for the Diagnosis of Thrombosis and Management of
Antithrombotic Therapies (FCSA).
Circulation 2009;119:2920-2927.
Study Question: What is the safety and efficacy of a standard-
ized perioperative bridging protocol using low molecular
weight heparin (LMWH) and tailored to thromboembolic
risk for patients receiving long-term oral anticoagulation
therapy (OAT) who require interruption of therapy during a
procedure?
Methods: This was an observational inception cohort study of
patients on OAT requiring interruption of therapy for surgi-
cal/invasive procedures. All those over age 18 without renal
insufficiency (creatinine <2.0 mg/dl) or contraindication to
LMWH were included. The bridging protocol stopped war-
farin 5 days preprocedure. Low-risk patients received once
daily prophylactic dosing of LMWH and those at high risk
received 70 anti-factor Xa U/kg twice daily. Primary out-
come was incidence of thromboembolism up to 30 days
postprocedure. 
Results: Of 1,262 patients, 295 (23.4%) were high risk.
There were five events noted, all in high-risk patients
(5/295, 1.7%), and all associated with bridging protocol
deviations. There were 15 major (1.2%) and 53 minor
(4.2%) episodes of bleeding. Major bleeding was associated
with high-risk patients, but not with the type of procedure.
Conclusions: This management bridging protocol, stratified by
thromboembolic risk, appears feasible, effective, and safe.
Safety in patients with mechanical valves has not been con-
clusively established.
Perspective: This registry documents a low incidence of
thromboembolic complications and bleeding with the use of
a standardized LMWH-based bridging protocol for periop-
erative interruption of warfarin therapy. This is a very
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patients with diabetes and stable CAD. Diabetic patients with
CAD do, however, remain at high risk of adverse events, and
almost 40% of the patients treated with initial medical therapy
required revascularization for worsening symptoms over 5
years. These high rates, combined with rapidly increasing
prevalence of type 2 diabetes, invoke the need for further
research to define more effective preventive therapies for
patients with diabetes mellitus.  
Summary written by: Hitinder S. Gurm, MD   
Coronary Artery Bypass Surgery Compared With
Percutaneous Coronary Interventions for
Multivessel Disease: A Collaborative Analysis of
Individual Patient Data From Ten Randomized Trials
Hlatky MA, Boothroyd DB, Bravata DM, et al.
Lancet 2009;373:1190-1197.
Study Question: How does coronary artery bypass grafting
(CABG) compare with percutaneous coronary intervention
(PCI) for multivessel coronary artery disease?
Methods: A meta-analysis of 10 randomized trials comparing
the effectiveness of CABG with PCI were included, and
patient data from these studies were pooled. Analyses were
done by the intention to treat and 7,812 patients were identi-
fied. PCI included balloon angioplasty in six trials and
bare-metal stents in four trials. The primary outcome included
the effect of different treatments on all-cause mortality.
Results: Median age was 61 years. Overall mortality was sim-
ilar between treatment groups, with a late mortality seen in
15% of CABG patients and 16% of PCI patients.
Composite outcomes of death or myocardial infarction were
also similar. Angina was significantly less in the CABG
group (14%) versus the PCI group (26%, p < 0.0001).
Diabetes increased the risk for death. Patient age also had
an effect on mortality, with patients ages 65 years or older
having a lower mortality following CABG versus PCI. The
presence of balloon angioplasty or bare-metal stenting as the
primary PCI method did not affect the treatment compari-
son of CABG versus PCI. The interactions of diabetes and
age were also present in both the balloon angioplasty and
bare-metal stent trials. 
Conclusions: Long-term mortality is similar in randomized
trials after CABG and PCI. However, for patients with dia-
betes and those ages 65 years or older, CABG may be a
better therapeutic option in the presence of multivessel dis-
ease.
Perspective: This is an important meta-analysis of the early
PCI trials, reinforcing the importance of diabetes and stratify-
frequently faced clinical problem, and data on which to base
such treatment are lacking. Current guidelines of the
American College of Chest Physicians suggest that patients
at increased risk should undergo bridging therapy with
either LMWH or intravenous unfractionated heparin (grade
1 recommendation, level of evidence C). This recommenda-
tion is based entirely on cohort studies. Unfortunately, the
nonrandomized nature of this study will perpetuate the clin-
ical question, and still leaves unanswered the necessity of
bridging or the optimal regimen. Randomized trials in this
area are desperately needed.  
Summary written by: James B. Froehlich, MD
Interventional Cardiology
A Randomized Trial of Therapies for Type 2
Diabetes and Coronary Artery Disease
The BARI 2 Study Group. 
N Engl J Med 2009;360:2503-2515.
Study Question: What is the optimal therapy for patients with
type 2 diabetes and coronary artery disease (CAD)?
Methods: The BARI-2 trial randomized 2,368 patients with
type 2 diabetes and stable CAD to undergo either revascu-
larization or optimal medical therapy, and to either insulin
sensitization or insulin provision. Randomization was strati-
fied according to percutaneous coronary intervention (PCI)
or coronary artery bypass grafting (CABG). The primary
endpoint was all-cause mortality and the secondary endpoint
was a composite of death, myocardial infarction, or stroke.
Average follow-up was 5.3 years.
Results: Among patients randomized to medical therapy,
42% required revascularization during follow-up. There was
no difference in either endpoint among patients randomized
to insulin sensitization or insulin provision, or in mortality
of patients randomized to initial medical therapy or revascu-
larization. A significant reduction was seen in the composite
secondary endpoint among patients randomized to CABG
compared to optimal medical therapy (22.4% vs. 30.5%),
predominantly driven by a reduction in myocardial infarction
(7.4 % vs. 14.6%). There was no difference in the secondary
endpoint among patients treated with PCI or medical ther-
apy in the PCI strata. 
Conclusions: There was no difference in survival of patients
with type 2 diabetes and stable CAD with early revascular-
ization versus initial optimal medical therapy, or insulin
sensitization versus insulin provision.
Perspective: The results of this trial provide further support to
use aggressive medical therapy as the first choice in most
JACC Vol. 54, No. 6, 2009
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ing the more appropriate therapy in the presence of multives-
sel coronary artery disease. It is somewhat surprising that the
number of diseased vessels may not necessarily affect the out-
come. An obvious counter to this remains the newer evolution
of the use of drug-eluting stents versus CABG in the treat-
ment of multivessel disease. The recent SYNTAX trial
suggests that CABG remains an important strategy.  
Summary written by: Himanshu J. Patel, MD    
Noninvasive Cardiology
Implementation of an Aortic Screening Program in
Clinical Practice: Implications for the Screen for
Abdominal Aortic Aneurysms Very Efficiently
(SAAAVE) Act
Lee ES, Pickett E, Hedayati N, Dawson DL, Pevec WC.
J Vasc Surg 2009;49:1107-1011.
Study Question: What are the efficacy and costs of a large-
scale screening effort for identifying abdominal aortic
aneurysms (AAAs) in patients in clinical practice?
Methods: In early 2007, the government enacted Medicare
coverage guidelines to screen persons at risk for the presence
of an AAA (the SAAAVE Act). Based on this Act, a
regional veterans affairs (VA) mandate for screening for
AAA was implemented. Data were extracted through the
Northern California VA Service Network to identify veteran
males 65-75 years of age who ever smoked at least 100 ciga-
rettes during their lifetime. An AAA was defined as an
aortic diameter 3.0 cm or greater.
Results: A total of 2,918 patients (average age 71 years) were
screened for AAA from February 2007 to February 2008.
An AAA was diagnosed in 5.1% (148/2,918) of patients.
Close to 10% of patients were inappropriately screened.
Aneurysm diameter distribution was as follows: 83%
(123/148) were 3.0-4.4 cm, 13% (19/148) were 4.5-5.5 cm,
and 4.1% (6/148) were greater than 5.5 cm. Isolated iliac
artery aneurysms were incidentally found in 0.1% (3) of
patients. Screening only cost $53 per patient.
Conclusions: AAA screening in a VA reflects the results
reported in other major clinical trials at a reasonable cost.
Large iliac artery aneurysms can also be identified as part of
this screening effort.
Perspective: This study confirms other trials, including the
MASS study. If done appropriately, nearly 5% of males
between the ages of 65 and 75 years will have an AAA.
Screening can be performed at a reasonable cost as well.
This suggests to me that we should broaden our net and
also perhaps look at females, especially those who smoke or
have a family history of AAAs.  
Summary written by: Gilbert Upchurch, Jr., MD 
Prevention/Vascular
Use of Blood Pressure Lowering Drugs in the
Prevention of Cardiovascular Disease: Meta-
Analysis of 147 Randomised Trials in the Context
of Expectations From Prospective Epidemiological
Studies
Law MR, Morris JK, Wald NJ.
BMJ 2009;338:b1665.
Study Question: Does blood pressure reduction alone explain the
effect of blood pressure lowering medications in preventing
coronary heart disease (CHD) and stroke, are there differ-
ences in efficacy among blood pressure lowering medications,
and is the benefit of blood pressure lowering medication use
related to subject’s history of cardiovascular disease?
Methods: This was a rigorous meta-analysis of randomized
trials of blood pressure lowering medications in which CHD
events and strokes were recorded. The analysis included 108
trials comparing study drug with placebo, 46 trials compar-
ing different antihypertensive medications, and seven trials
including three randomized groups which fell into both cat-
egories. The authors looked at effective blood pressure
lowering drugs on lowering blood pressure according to
dose, reduction in disease events per reduction in blood
pressure, and analyzed the results based on whether subjects
had a history of vascular disease, coronary disease, or stroke.
Results: Among 464,000 subjects, beta-blockers had an effect
above what would be expected for the blood pressure reduc-
tion achieved in preventing recurrent CHD events in people
with CHD. This benefit was seen only in the first few years
after MI, during which time there was a risk reduction of 31%
for beta-blockers in recent myocardial infarction (MI) versus
13% with no recent MI. Otherwise, the reduction in CHD
events and stroke were similar for a blood pressure reduction
of 10 mm mercury systolic or 5 mm mercury diastolic. This
was similar to reductions reported in a previous large cohort
study meta-analysis. All classes of blood pressure lowering
medications had similar benefit in preventing CHD events
and stroke, except for a slightly greater stroke reduction with
calcium channel blockers. Calcium channel blockers were
associated with a slightly lower reduction in incidence of heart
failure. There was a greater risk reduction with the use of two
blood pressure medications at half standard dose versus one
medication at standard dose, and roughly double the benefit
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of three medications at half standard dose when compared
with one medication at standard dose.
Conclusions: With the exception of an extra protective effect of
beta-blocker therapy shortly after MI, and a slightly increased
protective effect of calcium channel blockers for stroke, all
types of blood pressure medication have a similar, striking
benefit in reducing CHD events and stroke, suggesting a lack
of important pleiotropic effect. Guidelines on the use of blood
pressure medications could be simplified to offer medications
to subjects with all levels of blood pressure, and the results
suggest that blood pressure lowering is important in everyone
over a certain age.
Perspective: This enormous statistical tour de force provides
evidence of the dramatic benefit from blood pressure lowering
therapy, regardless of the agent chosen. These data also lend
strong support to the concept of adding a different class agent
rather than escalating dose when increasing antihypertensive
therapy. The authors make an argument for virtually universal
blood pressure lowering therapy.  
Summary written by: James B. Froehlich, MD
Predicting the 30-Year Risk of Cardiovascular
Disease: The Framingham Heart Study
Pencina MJ, D’Agostino RB Sr, Larson MG, Massaro JM, Vasan RS.
Circulation 2009;119:3078-3084.
Study Question: What are the factors included in a long-term
risk prediction tool?
Methods: Subjects from the Framingham Offspring cohort,
ages 20-59 years, were prospectively followed for cardiovascu-
lar disease (CVD) events including coronary death, myocardial
infarction, and stroke. Subjects were free of CVD or cancer at
baseline (1971-1974). Modified Cox modeling was used to
construct an algorithm for 30-year risk of hard CVD events.
Results: A total of 4,506 subjects were included (2,333
women). During the follow-up, 671 participants (219 women)
experienced a CVD event, and 622 (267 women) experienced
a non–CVD-related death. Thirty-year hard CVD event rates
were 7.6% for women and 18.3% for men. Stroke comprised
almost 40% of CVD events for women (<25% for men). Risk
factors including male sex, systolic blood pressure, total cho-
lesterol, HDL cholesterol, smoking, and diabetes mellitus
measured at baseline were predictive of incidence of CVD
events. Age was also significantly associated with long-term
CVD risk. These factors remained significant when updated
during follow-up.
Conclusions: Standard risk factors remain strong predictors of
CVD events over an extended period.
Perspective: These findings suggest that examining long-term
risk, particularly among young adults, will demonstrate to
patients and communities the need for strong risk factor pre-
vention among younger patients.  
Summary written by: Elizabeth A. Jackson, MD 
Central Obesity and Multivariate Cardiovascular
Risk as Assessed by the Framingham Prediction
Scores
Dhaliwal SS, Welborn TA.
Am J Cardiol 2009;103:1403-1407.
Study Question: Do measures of central obesity add to risk pre-
diction using the Framingham risk scores (FRS)?
Methods: Baseline data from a representative sample (strati-
fied by age and gender) of adult men from the Australian
Risk Factors Prevalence Survey, were used for the present
analysis. Exclusion criteria included a prior history of dia-
betes, myocardial infarction, or stroke. The cohort was
followed from 1989-2004. Baseline lipids, blood pressure,
current cigarette smoking, and obesity measures (body mass
index [BMI], waist circumference, and waist-to-hip ratio)
were collected.
Results: A total of 4,175 men were included, of which 346 (88
deaths due to cardiovascular disease [CVD] and 64 due to
coronary heart disease [CHD]) had died by 2004. The mean
age at baseline was 42.3 ± 13.1 years. Framingham risk equa-
tions were highly predictive of CHD and CVD deaths;
however, risks of death predicted by the FRS were signifi-
cantly greater than those observed (p < 0.0001). Both
waist-to-hip circumference and waist circumference were pre-
dictive of mortality; however, BMI was not. In multivariate
analysis, waist-to-hip circumference remained an independent
predictor of CHD mortality and both waist-to-hip circumfer-
ence and waist circumference remained independent
predictors of CVD mortality. These measures of central obe-
sity were strongly predictive of CHD and CVD among
subjects in the lower categories of FRS, whereas current
smoking appeared to increase the risk of death among those
in the higher range.
Conclusions: Central obesity was strongly and independently
predictive of CHD and CVD mortality, after accounting for
FRS category.
Perspective: These findings suggest that routine measurement
of waist circumference and/or waist-to-hip circumference in
the clinical setting may assist providers in identifying patients
at increased risk for CVD, particularly when the FRS is low.  
Summary written by: Elizabeth A. Jackson, MD 
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Predictive Value of Factor V Leiden and
Prothrombin G20210A in Adults With Venous
Thromboembolism and in Family Members of
Those With a Mutation: A Systematic Review
Segal JB, Brotman DJ, Necochea AJ, et al.
JAMA 2009;301:2472-2485.
Study Question: What is the clinical utility of measuring com-
mon prothrombotic mutations in factor V Leiden (FVL) and
prothrombin (G20210A) in patients with venous thromboem-
bolism (VTE) or in family members of mutation carriers?
Methods: MEDLINE, EMBASE, the Cochrane Library, the
Cumulative Index to Nursing and Allied Health Literature,
and PsycInfo were searched for relevant studies through
December 2008. Studies were included if they assessed rates
of VTE in individuals with a history of VTE who were
tested for FVL or prothrombin G20210A or in family mem-
bers of individuals with these mutations. 
Results: Out of 7,777 titles, 46 articles were included.
Heterozygosity and homozygosity for FVL in probands are
predictive of recurrent VTE compared with individuals with-
out FVL. Both heterozygosity and homozygosity for FVL
predict VTE in family members compared with family mem-
bers of adults without FVL. Heterozygosity for prothrombin
G20210A is not predictive of recurrent VTE in probands
compared with individuals without prothrombin G20210A.
Evidence is insufficient regarding the predictive value of pro-
thrombin G20210A homozygosity for recurrent VTE and the
risk of VTE in family members of individuals with prothrom-
bin G20210A. High-grade evidence supports that
anticoagulation reduces recurrent VTE events in probands
with either mutation. Low-grade evidence supports that this
risk reduction is similar to that in individuals with a history of
VTE and without mutations. 
Conclusions: Patients with FVL are at increased risk of recur-
rent VTE compared to those without. However, it is unknown
whether testing for FVL or prothrombin G20210A improves
outcomes in adults with VTE or their family members.
Perspective: Patients with VTE are commonly tested for pro-
thrombotic mutations. It is unclear how the genetic
information should be used when planning therapy. Similarly,
it is not apparent how testing family members of prothrom-
botic mutation carriers will alter management. Outcomes
studies on the clinical usefulness of genotyping prothrombotic
mutations in patients with VTE are needed. Until then, geno-
typing for these mutations is discretionary.  
Summary written by: Daniel T. Eitzman, MD 
Trajectories of Glycaemia, Insulin Sensitivity, and
Insulin Secretion Before Diagnosis of Type 2
Diabetes: An Analysis From the Whitehall II Study
Tabák AG, Jokela M, Akbaraly TN, Bunner EJ, Kivimaki M, Witte DR.
Lancet 2009;373:2215-2221.
Study Question: What is the time course of changes in glucose
metabolism prior to the onset of type 2 diabetes?
Methods: Data from the prospective occupational cohort
study (Whitehall II study) of 6,538 (71% male and 91%
white) British civil servants without diabetes mellitus were
analyzed at baseline. During a median follow-up of 9.7
years, 505 diabetes cases were diagnosed. Retrospective tra-
jectories of fasting and 2-hour post-load glucose,
homeostasis model assessment (HOMA) insulin sensitivity,
and HOMA β-cell function from up to 13 years before dia-
betes diagnosis (diabetic group) or at the end of follow-up
(nondiabetics) were assessed. 
Results: All metabolic measures followed linear trends in the
group of nondiabetics (10,989 measurements), except for
insulin secretion that did not change during follow-up. In the
diabetic group (801 measurements), a linear increase in fast-
ing glucose was followed by a steep quadratic increase (from
5.79 mmol/L to 7.40 mmol/L) starting 3 years before diagno-
sis of diabetes. Two-hour post-load glucose showed a rapid
increase starting 3 years before diagnosis (from 7.60 mmol/L
to 11.90 mmol/L), and HOMA insulin sensitivity decreased
steeply during the 5 years before diagnosis (to 86.7%).
HOMA β-cell function increased between years 4 and 3
before diagnosis (from 85.0% to 92.6%) and then decreased
until diagnosis (to 62.4%).
Conclusions: Changes in glucose concentrations, insulin sensi-
tivity, and insulin secretion occur as much as 3-6 years before
diagnosis of diabetes.
Perspective: Diabetes is considered a coronary disease equiva-
lent. However, several recent trials have demonstrated that
normalization of plasma glucose levels does not have a major
impact on cardiovascular risk. Thus, other factors associated
with diabetes are contributing to cardiovascular risk, and are
likely present prior to the onset of overt diabetes. These issues
highlight the importance of diagnosing the prediabetic state,
not only for prevention of diabetes, but for earlier targeting of
atherosclerosis with drug treatment such as statins.  
Summary written by: Daniel T. Eitzman, MD 
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